Histrelin_product_DataBase

Bioactivity	Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis[1][2][5].
Target	GnRH Receptor
Invitro	Histrelin (10-100 nM) stimulates the release of vasopressin (VP) from from isolated rat hypothalamo-neurohypophysial explants[4].Histrelin (100 nM) stimulates oxytocin (OT) release from the rat hypothalamo-neurohypophysial system[5].
In Vivo	Histrelin (0.1 mg/kg, subcutaneous injection) rescues the circulating LH concentrations in Csfmop/Csfmop mice[2].Histrelin (10,30, or 100 μg /day, subcutaneous injection) reduces the number of endometrial glands and atrophied the stroma in rabbits[3]. Animal Model:
Name	Histrelin
CAS	76712-82-8
Formula	C66H86N18O12
Molar Mass	1323.50
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Emma D Deeks, et al. Histrelin: in advanced prostate cancer. Drugs. 2010 Mar 26;70(5):623-30. [2]. P E Cohen, et al. Colony-stimulating factor-1 plays a major role in the development of reproductive function in male mice. Mol Endocrinol. 1997 Oct;11(11):1636-50. [3]. D W Hahn, et al. Development of an animal model for quantitatively evaluating effects of drugs on endometriosis. Fertil Steril. 1985 Sep;44(3):410-5. [4]. E Boczek-Leszczyk, et al. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of gonadotrophin-releasing hormone (GnRH), its analogues and melatonin. J Physiol Pharmacol. 2010 Aug;61(4):459-66. [5]. Marlena Juszczak, et al. Hypothalamic gonadotropin-releasing hormone receptor activation stimulates oxytocin release from the rat hypothalamo-neurohypophysial system while melatonin inhibits this process. Brain Res Bull. 2010 Jan 15;81(1):185-90.

PeptideDB

Histrelin

CAS: 76712-82-8 F: C66H86N18O12 W: 1323.50